- Časný záchyt kastračně rezistentního karcinomu prostaty2023 | First Faculty of Medicine
- PARP inhibitors in treating metastatic castration-resistant prostate cancer2023 | First Faculty of Medicine
- Treatment options of non-metastatic castration-resistant prostate cancer2018 | First Faculty of Medicine
- Sekvence léčby metastazujícího kastračně rezistentního karcinomu prostaty2017 | First Faculty of Medicine
- Current treatment options for metastatic castration-resistant prostate cancer2018 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Physical Education and Sport
- Darolutamide in the treatment of metastatic castrate-resistant prostate cancer2022 | First Faculty of Medicine
- Kastračně rezistentní karcinom prostaty - nové sekvence léčby v klinické praxi: zařazení nových inhibitorů androgenní osy v léčbě CRPC před docetaxel: proPublication without faculty affiliation
- The importance of cooperation between urologist and oncologist in the treatment of castration-resistant prostate cancer2014 | First Faculty of Medicine
- The importance of cooperation between urologist and oncologist in the treatment of castration-resistant2014 | First Faculty of Medicine
- Radium-223 dichloride (Xofigo) - management of the treatment of castration-resistant prostate cancer2014 | Third Faculty of Medicine
- Role of the Urologist in the Treatment of Castration-Resistant Prostate Cancer in the Czech Republic2013 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine
- Role of the Urologist in the Treatment of Castration-Resistant Prostate Cancer in the Czech Republic2013 | Publication without faculty affiliation
- Cabazitaxel for the treatment of metastatic castration-resistant prostate cancer2016 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Personalizovaný přístup ke kastračně rezistentnímu karcinomu prostatyPublication without faculty affiliation
- Sekvence abirateronu a enzalutamidu v léčbě metastatického kastračně rezistentního karcinomu prostaty2020 | First Faculty of Medicine
- Treatment of non‐metastatic castration‐resistant prostate cancer2023 | Third Faculty of Medicine
- Role of ARTAs in treating metastatic castration-resistant prostate cancer2019 | First Faculty of Medicine, Third Faculty of Medicine
- Enzalutamide in treatment of the metastatic castrate resistant prostate cancer2019 | First Faculty of Medicine
- Strategies sequential treatment of metastatic castration-resistant prostate cancer2020 | First Faculty of Medicine
- LOKÁLNÍ TERAPIE NEMETASTATICKÉHO KASTRAČNĚ REZISTENTNÍHO KARCINOMU PROSTATYPublication without faculty affiliation
- ARTA treatment of metastatic castration-resistant prostate cancer - case report2021 | First Faculty of Medicine
- Studie PROSPER - nová indikace "staronového" léku: enzalutamid v léčbě nemetastatického kastračně rezistentního karcinomu prostaty2020 | Third Faculty of Medicine
- Innovation in the treatment of castration – resistant prostate cancer2012 | First Faculty of Medicine
- Enzalutamide before chemotherapy in the treatment of metastatic castration-resistant prostate2019 | First Faculty of Medicine
- Novel therapeutic options in prostate cancer before chemotherapy2013 | First Faculty of Medicine
- Abiraterone acetate and quality of life of castration-resistant prostate cancer patients2013 | First Faculty of Medicine
- Účinnost enzalutamidu v léčbě metastatického kastračně rezistentního karcinomu prostaty2020 | First Faculty of Medicine
- Effectiveness and safety of abiraterone acetate treatment for metastatic castration-resistant prostate cancer post-chemotherapy2018 | First Faculty of Medicine
- Možnosti léčby karcinomu prostaty po selhání docetaxelu2015 | First Faculty of Medicine
- Systemic radiotherapy for prostate cancer with bone metastases2016 | First Faculty of Medicine